Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2026-05-11 @ 5:32 PM
Study NCT ID:
NCT06109467
Status:
RECRUITING
Last Update Posted:
2025-12-04
First Post:
2023-10-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
MCC-21917
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None